Cross-talk between the primary tumour and brain metastases enhances the efficacy of immune checkpoint inhibition
Melanoma brain metastases (MBrM) are devastating, occurring in up to 60% of melanoma patients and are increasing in incidence as systemic treatments improve. MBrM are notoriously difficult to treat and patients suffer from extremely poor survival rates, resulting in these patients being excluded fro...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Leeds
2016
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.702623 |